CN101579511A - Drug combination used for treating schizophrenia - Google Patents
Drug combination used for treating schizophrenia Download PDFInfo
- Publication number
- CN101579511A CN101579511A CNA2009101572064A CN200910157206A CN101579511A CN 101579511 A CN101579511 A CN 101579511A CN A2009101572064 A CNA2009101572064 A CN A2009101572064A CN 200910157206 A CN200910157206 A CN 200910157206A CN 101579511 A CN101579511 A CN 101579511A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- radix
- portions
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a drug combination used for treating schizophrenia. The drug combination is made from angelica, shizandra berry, Huperzia Serrata, radix curcumae, Morinda officinalis, liquorice, tuckahoe, seed of wild jujube, radix paeoniae alba, Fructus Gardeniae, acorus gramineus, safflower, dried orange peel, glossy privet fruit and rhizoma sparganii. The drug combination has easily available ingredients, obvious curing effect and no notable side effect.
Description
Technical field
The present invention relates to field of medicaments, particularly, the present invention relates to the schizoid pharmaceutical composition of a kind of treatment.
Background technology
Schizophrenia is one group of common mental sickness that the cause of disease is not bright, and it is to have that the inharmonious and ergasia of many-sided obstacles such as perception, thinking, emotion, behavior and ergasia and environment are inharmonious to be a kind of modal mental sickness of feature.EPDML studies show that, schizophrenia is 7.11 ‰ in China's city prevalence, and the prevalence in rural area is 4.26 ‰, and this has brought tremendous influence for family and society.
In recent years, people progressively tend to hommization, socialization for schizoid treatment, by treating to improve schizophrenic's social survival ability and quality of life.Clinical treatment is many based on Western medicine at present, but its side effect is bigger, and dependency is strong, has brought more hidden danger in for patient treatment.Therefore, people pay close attention to Therapeutic Method safer, better effects if more and more.Chinese medicine has just embodied its advantage in this respect.
The schizophrenia traditional Chinese medical science is referred to as " demented ", comprises " insane " and " mad " two big indications." demented " is all on the books in the historical various classics of TCM of China, and records many side's cards, and its pathology has been done concrete analysis, is referred to as " the anger due to excess of the liver deficiency is then feared " as Huangdi's Internal Classics; Errors in Medicine Corrected specifically describes and is " a demented disease is a coagulation of QI-blood, and brain gas and visceral-qi do not connect, as having a dream "; Zhang Zhongjing is also introduced relative theory and is said " its people's forgetfulness person must have blood-retention also ... " and this shows in treatise on Febrile Diseases, these treatises are all summed up the cause of disease that causes " demented " at disorder of QI and blood.Modern medicine thinks, its may with the change of hypothalamus neurotransmitter, mesolimbic system's dopamine functional activity excessively, factors such as prefrontal lobe dopamine activity decline, dysimmunity, heredity are relevant.These become seeks the schizoid newtype drug of treatment basis.Finished the present invention on this basis.
Summary of the invention
The purpose of this invention is to provide the schizoid pharmaceutical composition of a kind of treatment.
In order to realize purpose of the present invention, it is schizoid to the invention provides a kind of treatment
Pharmaceutical composition is characterized in that, it is the medicament of being made according to weight proportion by following ingredients:
Radix Angelicae Sinensis 1～10 weight portion Fructus Schisandrae Chinensis 1～5 weight portion Herba Lycopodii serrati 10～30 weight portions
Radix Curcumae 1～10 weight portion Radix Morindae Officinalis 10～30 weight portion Radix Glycyrrhizaes 1～10 weight portion
Poria 1～5 weight portion Semen Ziziphi Spinosae 5～15 weight portion Radix Paeoniae Albas 10～20 weight portions
Fructus Gardeniae 1～5 weight portion Rhizoma Acori Graminei 10～20 weight portion Flos Carthamis 1～5 weight portion
Pericarpium Citri Reticulatae 5～15 weight portion Fructus Ligustri Lucidi 1～5 weight portion rhizoma sparganic 1～5 weight portion.
Preferably, the schizoid pharmaceutical composition of treatment of the present invention is the medicament of being made according to weight proportion by following ingredients:
Radix Angelicae Sinensis 5 weight portion Fructus Schisandrae Chinensis 3 weight portion Herba Lycopodii serratis 20 weight portions
Radix Curcumae 5 weight portion Radix Morindae Officinaliss 20 weight portion Radix Glycyrrhizaes 5 weight portions
The Poria 3 weight portion Semen Ziziphi Spinosaes 10 weight portion Radix Paeoniae Albas 15 weight portions
Fructus Gardeniae 3 weight portion Rhizoma Acori Graminei 15 weight portion Flos Carthamis 3 weight portions
Pericarpium Citri Reticulatae 10 weight portion Fructus Ligustri Lucidi 3 weight portion rhizoma sparganic 3 weight portions.
The schizoid pharmaceutical composition of treatment of the present invention can be made various dosage forms according to technological means well-known to those skilled in the art, for example tablet (dispersible tablet), capsule, hard capsule, decoction etc.
The schizoid drug regimen composition formula of treatment of the present invention is reasonable, and composition is simple and easy to, and is evident in efficacy, and do not have significant side effects.
The specific embodiment
The following examples will give further instruction to the present invention, but not thereby limiting the invention.
Embodiment 1
Get Radix Angelicae Sinensis 500 grams, Fructus Schisandrae Chinensis 300 grams, Herba Lycopodii serrati 2000 grams, Radix Curcumae 500 grams, Radix Morindae Officinalis 2000 grams, Radix Glycyrrhizae 500 grams, Poria 300 grams, Semen Ziziphi Spinosae 1000 grams, the Radix Paeoniae Alba 1500 grams, Fructus Gardeniae 300 grams, Rhizoma Acori Graminei 1500 grams, Flos Carthami 300 grams, Pericarpium Citri Reticulatae 1000 grams, Fructus Ligustri Lucidi 300 grams, rhizoma sparganic 300 grams, pulverizer is pulverized, cross 80 mesh sieves, add microcrystalline Cellulose 3000 grams, mannitol 1000 grams, mix homogeneously, amidin pelletize with 10 weight %, dry back and crospolyvinylpyrrolidone 500 gram mix homogeneously are pressed 1000.
The test example
1. patient's situation: 40 routine patients, male 20 examples, women 20 examples, the oldest person is 70 years old, reckling is 28 years old, average 51 years old.The elder of medical history is 5 years, and the shortest person is 4 months, average 2 years 6 months.Be divided into treatment group and matched group, every group 20 example, wherein 2 groups of patient's parameters there was no significant differences.
2. diagnostic criteria: all cases all meet " Chinese mental sickness diagnostic criteria CCMD-3 " (Zhang Mingyuan. psychiatric department rating scale handbook [M]. Changsha: Hunan science tech publishing house, 1993.p81-95), got rid of and suffered from serious physical disease, epilepsy, organic disease person.Show as life sluggishness, paraphrenia clinically, speak to oneself solely laugh at, to people's indifference, unsociable and eccentric, fewly move, symptom such as complexion is pale, be afraid of cold.
3. Therapeutic Method: above-mentioned treatment group and matched group are observed 3 months time.The tablet of oral embodiment 1 preparation, every day 3 times, each 3 are organized in treatment.The oral LVANPING of matched group (available from Yangzhou Zhongbao Pharmaceutical Co., Ltd.), every day 2 times, 200 milligrams of each dosage.In therapeutic process, forbid other drug.
4. criterion of therapeutical effect: recovery from illness: the complete obiteration of psychotic disease symptom, thinking is more normal, is emotionally stable, and it is normal that social function is recovered.Produce effects: the psychotic disease symptom is most of to disappear, and thinking is more normal, is emotionally stable, and social function is obviously recovered, and insight has part to recover.Effectively: the psychotic disease symptom partly disappears, and thinking is more random, flat affect, and insight partly recovers.Invalid: symptom does not have improvement, no insight.
5. therapeutic outcome
The result who treats after 3 months is as shown in table 1 below.
Table 1 liang group clinical treatment result's comparison
The effect of treatment group as seen from the above table, obviously is better than the therapeutic effect of matched group.
6. untoward reaction
Observe 7 examples and sialorrhea occurs in matched group, feeling sick appears in 8 examples, vomiting, and abnormal liver function appears in 2 examples, and electrocardiographic abnormality appears in 2 examples.And in the treatment group, only have 2 examples to occur feeling sick, vomitting, do not find other untoward reaction in addition.This shows that the untoward reaction of treatment group is significantly less than the untoward reaction of matched group.
Claims (3)
1. treat schizoid pharmaceutical composition for one kind, it is characterized in that it is the medicament of being made according to weight proportion by following ingredients:
Radix Angelicae Sinensis 1～10 weight portion Fructus Schisandrae Chinensis 1～5 weight portion Herba Lycopodii serrati 10～30 weight portions
Radix Curcumae 1～10 weight portion Radix Morindae Officinalis 10～30 weight portion Radix Glycyrrhizaes 1～10 weight portion
Poria 1～5 weight portion Semen Ziziphi Spinosae 5～15 weight portion Radix Paeoniae Albas 10～20 weight portions
Fructus Gardeniae 1～5 weight portion Rhizoma Acori Graminei 10～20 weight portion Flos Carthamis 1～5 weight portion
Pericarpium Citri Reticulatae 5～15 weight portion Fructus Ligustri Lucidi 1～5 weight portion rhizoma sparganic 1～5 weight portion.
2. the schizoid pharmaceutical composition of treatment according to claim 1 is characterized in that, it is the medicament of being made according to weight proportion by following ingredients:
Radix Angelicae Sinensis 5 weight portion Fructus Schisandrae Chinensis 3 weight portion Herba Lycopodii serratis 20 weight portions
Radix Curcumae 5 weight portion Radix Morindae Officinaliss 20 weight portion Radix Glycyrrhizaes 5 weight portions
The Poria 3 weight portion Semen Ziziphi Spinosaes 10 weight portion Radix Paeoniae Albas 15 weight portions
Fructus Gardeniae 3 weight portion Rhizoma Acori Graminei 15 weight portion Flos Carthamis 3 weight portions
Pericarpium Citri Reticulatae 10 weight portion Fructus Ligustri Lucidi 3 weight portion rhizoma sparganic 3 weight portions.
3. the schizoid pharmaceutical composition of treatment according to claim 1 and 2 is characterized in that described medicament is tablet, dispersible tablet, capsule, hard capsule, decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101572064A CN101579511B (en) | 2009-07-02 | 2009-07-02 | Drug combination used for treating schizophrenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101572064A CN101579511B (en) | 2009-07-02 | 2009-07-02 | Drug combination used for treating schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101579511A true CN101579511A (en) | 2009-11-18 |
| CN101579511B CN101579511B (en) | 2011-08-31 |
Family
ID=41361917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101572064A Expired - Fee Related CN101579511B (en) | 2009-07-02 | 2009-07-02 | Drug combination used for treating schizophrenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101579511B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125678A (en) * | 2010-10-27 | 2011-07-20 | 宋爱民 | Chinese medicinal preparation for treating hysteria disease |
| CN102579806A (en) * | 2012-03-23 | 2012-07-18 | 田冬梅 | Drug combination for treating schizophrenia |
| CN102836324A (en) * | 2012-09-20 | 2012-12-26 | 李龙飞 | Decoction for treating schizophrenia |
| CN104189454A (en) * | 2014-09-10 | 2014-12-10 | 李�浩 | Medicament for treating schizophrenia and preparation method thereof |
| CN104288684A (en) * | 2014-10-11 | 2015-01-21 | 中山百鸥医药科技有限公司 | Medicinal composition for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111058C (en) * | 2000-11-29 | 2003-06-11 | 段青松 | Vesania-treating medicine |
| CN100408080C (en) * | 2003-06-04 | 2008-08-06 | 郑淑英 | Heart quieting and orifice opening capsule and its preparation |
| CN1327890C (en) * | 2004-06-01 | 2007-07-25 | 刘胜先 | Chinese medicinal preparation for treating schizophrenia, its preparation and application method |
| CN100341564C (en) * | 2005-11-17 | 2007-10-10 | 王炎兴 | Traditional Chinese medicine for treating schizophrenia |
-
2009
- 2009-07-02 CN CN2009101572064A patent/CN101579511B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125678A (en) * | 2010-10-27 | 2011-07-20 | 宋爱民 | Chinese medicinal preparation for treating hysteria disease |
| CN102125678B (en) * | 2010-10-27 | 2012-05-30 | 宋爱民 | Chinese medicinal preparation for treating hysteria disease |
| CN102579806A (en) * | 2012-03-23 | 2012-07-18 | 田冬梅 | Drug combination for treating schizophrenia |
| CN102836324A (en) * | 2012-09-20 | 2012-12-26 | 李龙飞 | Decoction for treating schizophrenia |
| CN102836324B (en) * | 2012-09-20 | 2013-11-13 | 李龙飞 | Decoction for treating schizophrenia |
| CN104189454A (en) * | 2014-09-10 | 2014-12-10 | 李�浩 | Medicament for treating schizophrenia and preparation method thereof |
| CN104288684A (en) * | 2014-10-11 | 2015-01-21 | 中山百鸥医药科技有限公司 | Medicinal composition for treating schizophrenia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101579511B (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101579511B (en) | Drug combination used for treating schizophrenia | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN103272127B (en) | Preparation for treating epilepsy | |
| CN102462825A (en) | Compound traditional Chinese medicine for treating depression | |
| CN106237268A (en) | One treats schizoid pharmaceutical composition and application thereof | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN102657819B (en) | Drug combination for treating dysthymic disorder | |
| CN102114195A (en) | Anti-drug capsule prepared from pure traditional Chinese medicines | |
| CN101411770B (en) | Medicament for treating blood stasis accumulation type multiple sclerosis symptoms | |
| CN103550477B (en) | Medicament for treating herpes zoster | |
| CN103041050A (en) | Medicine for treating impetigo | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN102961726B (en) | Agentia for treating schizophrenia | |
| CN102266482B (en) | Medicament for treating mania | |
| CN108635457A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating constipation | |
| CN102836354A (en) | Medicament for treating depression | |
| CN102488864B (en) | Medicinal composition for treating herpes zoster | |
| CN102526373B (en) | Medicinal composition for treating infantile anorexia | |
| CN102961725B (en) | Agentia for treating dysthymia | |
| CN103961429B (en) | Traditional Chinese medicine composition having effects of moving qi and invigorating blood circulation and preparation method thereof | |
| CN1256963C (en) | Antifatigue medicine and its preparation method | |
| CN102552790B (en) | Medicament for stopping vomit after radiography | |
| CN100478011C (en) | Medicine for treating AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG Free format text: FORMER OWNER: CHEN XUEMEI Effective date: 20130716 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272051 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130716 Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin Address before: 272051 Jining psychiatric hospital of Shandong Province Patentee before: Chen Xuemei |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110831 Termination date: 20160702 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |